Results 71 to 80 of about 6,336 (192)

Efgartigimod Versus Lymphoplasmapheresis as Preoperative Rapid Antibody‐Clearing Therapies for Thymectomy in Generalized Myasthenia Gravis: Effectiveness, Safety and Cost Outcomes Compared to Conventional Preparation

CNS Neuroscience &Therapeutics, Volume 32, Issue 6, June 2026.
In this exploratory study, no statistically significant differences in effectiveness, safety, or cost were observed between EFG and LPE, nor between RACT and oral immunosuppressants for pre‐thymectomy preparation in MG. These findings are hypothesis‐generating and warrant prospective validation.
Qian Zhou, Ting He, Yuanda Cheng, Kangzhi Chen, Yuzhen Ouyang, Xiaohua Dong, Guanzhong Shi, Zeyi Wen, Huan Yang   +8 more
wiley   +1 more source

Frontalis sling procedure for ocular myasthenia gravis

Clinical Ophthalmology, 2012
Shinichi Asamura1, Hirohiko Kakizaki2, Mitsuhiro Enjyo1, Takahiro Hashimoto1, Noritaka Isogai11Department of Plastic and Reconstructive Surgery, Kinki University School of Medicine, Osakasayama, Osaka, Japan; 2Department of Ophthalmology, Aichi Medical ...
Isogai N, Hashimoto T, Enjyo M, Kakizaki H, Asamura S   +4 more
doaj  

Shifting From Systemic to Precision‐Targeted Complement Therapies: Opportunities and Hurdles

European Journal of Immunology, Volume 56, Issue 6, June 2026.
Complement therapeutics have expanded considerably, but systemic inhibitors remain limited by infection risks, breakthrough events, and loss of physiological functions. Emerging targeted approaches aim for organ‐, tissue‐, or cell‐specific modulation of complement activity, potentially offering greater precision while reducing treatment burden and ...
Marco Mannes, Wioleta M. Zelek, Leendert A. Trouw   +2 more
wiley   +1 more source

Thymectomy in the treatment of ocular myasthenia gravis

The Journal of Thoracic and Cardiovascular Surgery, 2001
Thymectomy is an effective and accepted treatment for myasthenia gravis, but thymectomy for ocular myasthenia gravis (Osserman stage I) is controversial.To assess the efficacy and propriety of thymectomy for the treatment of ocular myasthenia gravis.We conducted a review and follow-up of all patients who had thymectomy for the treatment of ocular ...
Peter F. Roberts, VENUTA, Federico, RENDINA, Erino Angelo, DE GIACOMO, Tiziano, COLONI, Giorgio Furio, David M. Follette, David P. Richman, John R. Benfield   +7 more
openaire   +2 more sources

The Anti-Acetylcholine Receptor Antibody Test in Suspected Ocular Myasthenia Gravis

Journal of Ophthalmology, 2014
Aim. To estimate the clinical significance of anti-acetylcholine receptor antibody (anti-AChR-Ab) levels in suspected ocular myasthenia gravis. Methods. In total, 144 patients complaining of fluctuating diplopia and ptosis were evaluated for serum levels
Jung Jin Lee, Kyung Min Koh, Ungsoo Samuel Kim   +2 more
doaj   +1 more source

Ocular Myasthenia Gravis: Controversies and Updates

Current Neurology and Neuroscience Reports, 2013
The majority of patients with myasthenia gravis (MG) initially present with ocular symptoms. An unresolved question is whether there are clinical features at onset to guide clinicians to predict an individual patient's conversion risk from ocular MG (OMG) to generalized disease, or "secondary generalized MG" (SGMG), that is, a prognostic model.
Wong, S, Huda, S, Vincent, A, Plant, G
openaire   +3 more sources

Retrospective Evaluation of Dual Specialty Ports in Therapeutic Apheresis

Journal of Clinical Apheresis, Volume 41, Issue 3, June 2026.
ABSTRACT Dual specialty ports were evaluated for safety and efficacy in therapeutic apheresis by analyzing outcomes across 97 port placement events in 88 patients, focusing on two configurations: dual Bard PowerFlow (BP2) and a combination of Bard PowerFlow with AngioDynamics SmartPort (BP + AD).
Mugtaba Swar‐Eldahab, Barnabas Obeng‐Gyasi, Paul Haste, Matthew Krosin   +3 more
wiley   +1 more source

A Rare Clinical Presentation of Variegate Porphyria

Molecular Genetics &Genomic Medicine, Volume 14, Issue 6, June 2026.
WGS redirected the diagnostic focus, underscoring the complex interplay between porphyria and a potential MYMK‐related neuromuscular phenotype. ABSTRACT Background Variegate porphyria is a rare heme biosynthesis disorder caused by pathogenic variants in the PPOX gene.
I. Viakhireva, A. Murtazina, A. Orlova, N. Makretskaya, S. Nikitin, M. Skoblov   +5 more
wiley   +1 more source

Ocular Myasthenia Gravis and Thymus Gland Hyperplasia–A Case Report

TNOA Journal of Ophthalmic Science and Research
Myasthenia gravis (MG) is caused by antibodies directed at acetylcholine receptors or functionally related proteins in the postsynaptic membrane at the neuromuscular junction.
Sujit Das
doaj   +1 more source

Experience Using Efgartigimod to Treat Juvenile Myasthenia Gravis in China: A Multicenter Retrospective Study

Muscle &Nerve, Volume 73, Issue 6, Page 1025-1031, June 2026.
ABSTRACT Introduction/Aims Current therapeutic management of juvenile myasthenia gravis (JMG) predominantly relies on conventional immunosuppressive therapies and expert consensus extrapolated from adult data, creating a critical gap in high‐quality, pediatric‐specific clinical evidence.
Jing Lin, Guoyan Qi, Susan Luo, Qilong Jiang, Bitao Bu, Min Liu, Yuzhen Wei, Meigui Han, Junhong Yang, Zhilan Zhao, Lili Zhang, Yifan Zhang, Haoyou Xu, Xingjie Hao, Zhijun Li   +14 more
wiley   +1 more source